LifeSci Capital Initiates Coverage of Tracon Pharmaceuticals

ACCESSWIRE
0

Developing Angiogenesis Inhibitor that Complements VEGF Inhibitors in Multiple Phase 2 Oncology Trials and Wet AMD; Report Available here: http://www.lifescicapital.com/equity-research/tracon/

NEW YORK, NY / ACCESSWIRE / October 5, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Tracon Pharmaceuticals (TCON), a biopharmaceutical company developing treatments for oncology, ophthalmology, and fibrosis. The Company's lead candidate, TRC105, is an antibody that targets endoglin, a cell membrane receptor required for angiogenesis. Tracon is currently conducting Phase II trials of TRC105 in patients with soft tissue sarcoma, renal cell carcinoma, glioblastoma, hepatocellular carcinoma, and choriocarcinoma.

TRC105 is an anti-angiogenic antibody designed to target endoglin in proliferating endothelial and tumor cells. Angiogenesis inhibition with vascular endothelial growth factor (VEGF) inhibitors is an effective cancer treatment, but most patients eventually develop resistance to therapy. Endoglin expression is associated with tumor cell proliferation, and is thought to be an important contributor to VEGF resistance. These factors make TRC105 a potentially effective treatment for a broad range of cancers. It is also expected to be a relevant therapeutic for ophthalmic indications caused by angiogenesis and fibrosis. The Company partnered with Santen Pharmaceutical for the development of TRC105 in wet AMD, and Santen expects to initiate a Phase I trial later this year. Tracon received a $3 million milestone payment following IND filing by Santen for DE-122, the ophthalmic formulation of TRC105, and is eligible for an additional $152 million in remaining milestones, in addition to royalties from the deal.

In a 49 page Initiation Report LifeSci Capital explains the clinical data supporting TRC105's potential in several oncology indications. We outline the market opportunity for each disease and discuss the landscape of approved agents and those in development.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Tracon Pharmaceuticals as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

Advertisement

Recommended Stories

  • Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million

    Jeff Bezos amassed his wealth through Amazon stocks and owns hundreds of millions of dollars worth of real estate, but one of his most valuable possessions may surprise you: art. Among his collection is the renowned piece "Hurting the Word Radio #2 (1964)" by Ed Ruscha, purchased by Bezos for almost $53 million. This artwork, a prime example of Ruscha’s text-based paintings, stands as a signature piece in Bezos’ collection. As concerns over stock market volatility persist, the world’s wealthiest

  • Warren Buffett's Latest $2.6 Billion Buy Brings His Total Investment in This Stock to More Than $77 Billion in Under 6 Years

    The Oracle of Omaha has purchased shares of his favorite stock for 23 consecutive quarters.

  • Anthropic now lets kids use its AI tech -- within limits

    AI startup Anthropic is changing its policies to allow minors to use its generative AI systems -- in certain circumstances, at least. Announced in a post on the company's official blog Friday, Anthropic will begin letting teens and preteens use third-party apps (but not its own apps, necessarily) powered by its AI models so long as the developers of those apps implement specific safety features and disclose to users which Anthropic technologies they're leveraging. In a support article, Anthropic lists several safety measures devs creating AI-powered apps for minors should include, like age verification systems, content moderation and filtering and educational resources on "safe and responsible" AI use for minors.

  • Bluesky now lets you personalize main Discover feed using new controls

    Bluesky is now allowing users to personalize their main Discover feeds. The social network is rolling out an updated version of its app that lets users offer feedback about its algorithmic feed so they can better customize it using "Show more like this" and "Show less like this" buttons in a post's menu to choose which content the algorithm surfaces. The change will help Bluesky users create a timeline that takes into consideration their own preferences, not what the company thinks they should see.

  • With Apple entering the fight, the AI chip wars have gone nuclear

    The AI PC chip wars are going nuclear as Apple officially joins the fight with its M4 processor.

  • I Finally Decided to Cut My Losses and Sell This Stock -- Here's Why

    This real estate technology company could be hit hard by a changing real estate market.

  • Palantir Stock (NYSE:PLTR): Should You Buy the Post-Earnings Dip?

    Palantir stock (NYSE:PLTR) dipped by about 16% after its Q1 earnings report, prompting me to ponder whether this downturn presents a buying opportunity. Notably, Palantir showcased yet another quarter of solid revenue growth, promising client base expansion, and strong profitability metrics. That said, concerns persist regarding the stock’s elevated valuation. Consequently, despite my belief in Palantir’s long-term prospects as a shareholder, I maintain a neutral stance towards the stock at pres

  • Stock Market News for May 10, 2024

    Wall Street closed sharply higher on Thursday, with interest rates still dominating the proceedings.

  • 3 Rock-Solid Dividend Stocks That Are Ideal for Retirees

    These are low-risk stocks with high yields.

  • McDonald’s Will Offer a $5 Meal Deal to Lure Customers Back Into Stores

    (Bloomberg) -- McDonald’s Corp. is looking to launch a $5 meal deal in the US that the burger chain is betting can lure penny-pinching consumers back in.Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedApple Nears Deal With OpenAI to Put ChatGPT on iPhoneBiden Set to Hit China EVs, Strategic Sectors With TariffsJim Simons, Code Breaker Who Mastered Investing, Dies at 86Ice Cube’s Big3 Basketball League Sells Its First Team in $10 Million DealThe deal could